Clinical Trials
21 trialsNCT06995872 2026-05-22
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07172958 2026-05-22
SABRE
Children's National Research Institute
Phase 1 Recruiting
NCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT07584499 2026-05-13
MRG003
Sun Yat-sen University
Phase 1 Recruiting
NCT06500819 2026-05-07
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Stanford University
Phase 1 Recruiting
NCT04084067 2026-04-30
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04308330 2026-04-15
NYMC195
New York Medical College
Phase 1 Recruiting
NCT03721068 2026-03-27
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT06041516 2026-03-27
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06104488 2026-02-25
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05650749 2025-12-29
GPC2
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT05400603 2025-12-26
Aflac-NBL-2002
Emory University
Phase 1 Recruiting
NCT07007117 2025-12-26
PHOX2B
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT02508038 2025-10-16
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT03294954 2025-09-19
GINAKIT2
Baylor College of Medicine
Phase 1 Recruiting
NCT07027748 2025-07-14
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06485947 2025-07-08
DBPilot
Princess Maxima Center for Pediatric Oncology
Phase 1 Recruiting
NCT06674265 2025-04-09
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Kian Immune Cell Company
Phase 1 Recruiting
NCT05701306 2025-02-25
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT06631391 2025-02-20
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
Sun Yat-sen University
Phase 1 Recruiting
NCT06751134 2025-02-07
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Nanjing Children's Hospital
Phase 1 Recruiting